4-methylene-2-octyl-5-oxofuran-3-carboxylic-acid has been researched along with Hypertension--Pulmonary* in 2 studies
2 other study(ies) available for 4-methylene-2-octyl-5-oxofuran-3-carboxylic-acid and Hypertension--Pulmonary
Article | Year |
---|---|
Involvement of fatty acid synthase in right ventricle dysfunction in pulmonary hypertension.
Apart from pulmonary vascular resistance and right ventricle (RV) hypertrophy, metabolic dysfunction also plays a major role in pathophysiology of pulmonary hypertension (PH). Recently, we have shown that fatty acid synthase (FAS), an enzyme involved in de novo fatty acid synthesis, plays a pivotal role in PH as its inhibition was protective and decreased pulmonary vascular remodelling, RV pressure and hypertrophy and improved endothelial functions. However, the precise mechanism behind protective effect of FAS inhibition on right ventricle dysfunction associated with PH is not completely understood. Therefore, the present study delineated the mechanism of protective effect of FAS inhibition on RV dysfunction associated with PH. siRNA mediated inhibition of FAS reduced FAS expression, hypertrophy, inflammation, apoptosis, autophagy and improved the glucose oxidation, mitochondrial membrane potential and ATP level in hypoxic cardiomyocytes. In monocrotaline (MCT) treated rats, FAS inhibition by C75 (2 mg/kg, i.p., once a week from 21 to 35 days) decreased the expression and activity of FAS and palmitate level. C75 also improved cardiac functions and mitochondrial membrane potential leading to decreased apoptosis in RV of MCT treated rats. In conclusion, our study reveals that inhibition of FAS decreases RV hypertrophy and improves cardiac function associated with PH by perking up metabolic functions. Topics: 4-Butyrolactone; Animals; Animals, Newborn; Cells, Cultured; Fatty Acid Synthase, Type I; Gene Expression Regulation, Enzymologic; Hypertension, Pulmonary; Hypertrophy, Right Ventricular; Male; Monocrotaline; Myocytes, Cardiac; Rats; Rats, Sprague-Dawley; RNA, Small Interfering; Ventricular Remodeling | 2019 |
Inhibition of fatty acid synthase is protective in pulmonary hypertension.
In pulmonary hypertension (PH), similar to cancer, there is altered energy metabolism, apoptosis resistance and cellular proliferation leading to pulmonary vascular remodelling. Proliferating cells exhibit higher rate of de novo fatty acid synthesis to provide lipids for membrane formation and energy production. As inhibition of de novo fatty acid synthesis proved protective in cancer experimentally, therefore, it was hypothesized that modulation of de novo fatty acid synthesis by inhibition of fatty acid synthase (FAS) may prove beneficial for PH.. For in vitro studies, human pulmonary artery smooth muscle cells (HPASMCs) were exposed to hypoxia and to induce PH in vivo, rats were treated with monocrotaline (MCT). FAS was inhibited by siRNA (60 nM) and C75 (2 mg·kg(-1) , i.p. once a week for 5 weeks) in in vitro and in vivo studies respectively.. Increased expression and activity of FAS were observed in hypoxic HPASMCs and lungs of MCT-treated rats. Inhibition of FAS increased apoptosis and glucose oxidation, but decreased proliferation and markers of autophagy, glycolysis and insulin resistance in hypoxic HPASMCs. It also improved the mitochondrial functions as evident by increased level of ATP and restoration of normal level of ROS and membrane potential of mitochondria. In MCT-treated rats, FAS inhibition decreased right ventricular pressure, hypertrophy, pulmonary vascular remodelling (increased apoptosis and decreased proliferation of cells) and endothelial dysfunction in lungs.. Our results demonstrate that FAS activity is modulated in PH, and its inhibition may provide a new therapeutic approach to treat PH. Topics: 4-Butyrolactone; Animals; Apoptosis; Cells, Cultured; Dose-Response Relationship, Drug; Enzyme Inhibitors; Fatty Acid Synthases; Humans; Hypertension, Pulmonary; Male; Rats; Rats, Sprague-Dawley; Structure-Activity Relationship | 2016 |